<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157738</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00114078</org_study_id>
    <nct_id>NCT04157738</nct_id>
  </id_info>
  <brief_title>A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus</brief_title>
  <official_title>Fixed Dose for Fixed Carbohydrates vs. Variable Dosing for Variable Carbohydrates: A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes mellitus (T1DM) is a challenging medical disorder, especially in children and&#xD;
      adolescents. In order to prevent the chronic complications of hyperglycemia, the maintenance&#xD;
      of near-normal glycemic control must be balanced with minimizing hypoglycemia. Although many&#xD;
      pediatric endocrinologists provide an ICR plan for their newly diagnosed patients with T1DM,&#xD;
      fixed dosing and other forms of insulin delivery are available. This proposal is designed to&#xD;
      compare children and adolescents with newly diagnosed T1DM using a fixed insulin dose for&#xD;
      fixed carbohydrate mealtime regimen (FIXED group) to children and adolescents with newly&#xD;
      diagnosed T1DM using an ICR with variable carbohydrate intake (ICR group) mealtime regimen.&#xD;
      In addition to determining the feasibility for a subsequently larger clinical trial, the aims&#xD;
      of this investigator-initiated, prospective proposal, is twofold. The first is to determine&#xD;
      if the caregivers of diabetics using a fixed insulin for fixed carbohydrate regimen (FIXED&#xD;
      group) experience less anxiety than the caregivers of those using an ICR with variable&#xD;
      carbohydrate intake regimen (ICR group) at 1- and 4-months post-randomization. The second is&#xD;
      to determine if diabetics utilizing a fixed insulin for fixed carbohydrate regimen (FIXED&#xD;
      group) have decreased glycemic variability (GV) than those using an ICR with variable&#xD;
      carbohydrate intake regimen (ICR group) at 1- and 4-months post-randomization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although children and adolescents with T1DM have much more freedom with the amount of food&#xD;
      (carbohydrates) they eat while using an ICR at mealtime, the difficulty in determining the&#xD;
      amount of insulin needed, how and when to adjust the ICR, the difficulty with understanding&#xD;
      the basics of managing T1DM, and the adaptation to a new lifestyle with T1DM may be more&#xD;
      complicated than utilizing a simple plan that includes a fixed amount of insulin and fixed&#xD;
      number of carbohydrates, at least for the first few months after diagnosis. As complicated as&#xD;
      it is for children, adolescents, and their caregivers to learn how to manage T1DM after being&#xD;
      discharged home in usually &lt; 48 hours after diagnosis, a more simplified insulin regimen at&#xD;
      mealtime may provide the family of and the child or adolescent with newly diagnosed T1DM with&#xD;
      less stress and anxiety while still maintaining adequate glycemic control. Twenty - 40&#xD;
      subjects will be recruited at Children's Hospital of Atlanta (CHOA) at Egleston and will be&#xD;
      randomized to either the FIXED group or the ICR group according to a computer-generated&#xD;
      random sampling table. The subject and his/her caregivers will receive diabetes education&#xD;
      while in the hospital in standard fashion. The subject and his/her caregivers will receive&#xD;
      glucose monitoring education and training prior to hospital discharge. The subject and&#xD;
      his/her caregivers will also receive a paper log to record the blood sugars, number of&#xD;
      carbohydrates consumed and insulin administered at each meal throughout the day.&#xD;
&#xD;
      Prior to discharge, all subjects will receive a regimen that includes a: 1) Meal-time insulin&#xD;
      and carbohydrate regimen (# of units of insulin, # of carbohydrates, and/or ICR); 2) Daily&#xD;
      dose of Glargine; 3) Hyperglycemia correction regimen for blood glucose levels &gt; 199 mg/dL;&#xD;
      and 4) Hypoglycemia treatment regimen for blood glucose levels &lt; 70 mg/dL and/or symptomatic.&#xD;
&#xD;
      As per standard diabetes care, caregivers will report all blood glucose levels every day (to&#xD;
      the study investigators) until the subject's initial clinic visit 4-6 weeks after diagnosis.&#xD;
      All insulin adjustments will be made by the study investigators.&#xD;
&#xD;
      After the subject's first clinic visit, caregivers will contact the study investigators once&#xD;
      a week to report blood glucose levels and the investigators will make adjustments as needed.&#xD;
&#xD;
      All the diabetes clinic visits will occur at the Center for Advanced Pediatrics (CAP),&#xD;
      approximately three miles from CHOA-Egleston Hospital. Subjects will attend clinic with one&#xD;
      or more of the investigators approximately 1 and 4 months after enrollment.&#xD;
&#xD;
      At each clinic visit, subjects (and their caregivers) will answer standard diabetes&#xD;
      questions, subjects will undergo a physical examination, and subjects' objective data (vital&#xD;
      signs, glucose meter (GM) data, insulin dosing, and carbohydrate intake) will be collected by&#xD;
      the study personnel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Actual">December 17, 2020</completion_date>
  <primary_completion_date type="Actual">December 17, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of All Consented Participants</measure>
    <time_frame>4 months post-intervention</time_frame>
    <description>The capacity for recruitment was assessed, including all subjects that signed the Informed Consent Form (ICF).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants That Completed All Visits</measure>
    <time_frame>4 months post-intervention</time_frame>
    <description>Number of participants that were able to complete all study visits, including the visits in-person at 1 month and 4 months post-randomization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention</measure>
    <time_frame>1 month post-intervention and 4 months post-intervention</time_frame>
    <description>Caregiver treatment adherence was assessed using a blood glucose log. Subjects and caregivers recorded blood glucose levels and the amount/type of insulin given. This data was used to calculate adherence as a percentage ranging from 0% (no adherence) to 100% (full adherence).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caregiver Anxiety</measure>
    <time_frame>Baseline, 1 month post-intervention, 4 months post-intervention</time_frame>
    <description>Caregiver anxiety was measured with the &quot;parental stress scale&quot;. Caregivers completed the &quot;parental stress scale&quot; at initial enrollment and at each clinic follow up visit. The Parental Stress Scale includes 18 questions that are rated from 1 (strongly disagree) to 5 (strongly agree). Scoring ranges from 18 - 90. The higher the score, the higher the stress and anxiety level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention</measure>
    <time_frame>1 month post-intervention, 4 months post-intervention</time_frame>
    <description>The GV was calculated in all subjects using the average blood glucose levels collected from the daily blood glucose paper log. A subjective qualification system was used to label each subject's GV based on their blood glucose levels and an established glucose monitoring (GM) data system. Subjects are considered to have appropriate GV if their blood glucose levels are in the range of 80 mg/dL - 180 mg/dL. Percentage of participants within each specific average BG range is shown.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Fixed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin to carbohydrate ratio (ICR) Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapid-Acting Insulin</intervention_name>
    <description>Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)</description>
    <arm_group_label>Fixed Group</arm_group_label>
    <arm_group_label>Insulin to carbohydrate ratio (ICR) Group</arm_group_label>
    <other_name>Lispro, Aspart, glulisine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long acting insulin</intervention_name>
    <description>Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
    <arm_group_label>Fixed Group</arm_group_label>
    <arm_group_label>Insulin to carbohydrate ratio (ICR) Group</arm_group_label>
    <other_name>Glargine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have Confirmed diagnosis of T1DM based on the most recent ADA criteria&#xD;
&#xD;
          -  Be 7 - 15 years of age&#xD;
&#xD;
          -  Begin monitoring with a glucose monitor prior to discharge from the hospital&#xD;
&#xD;
          -  Have the ability to understand and be willing to adhere to the study protocol&#xD;
&#xD;
          -  English or Spanish speakers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a clinically significant major organ system disease&#xD;
&#xD;
          -  Be on glucocorticoid therapy&#xD;
&#xD;
          -  Have Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Have Polycystic Ovarian Syndrome (PCOS)&#xD;
&#xD;
          -  Have a BMI &gt; 85th %ile&#xD;
&#xD;
          -  Have Acanthosis Nigricans&#xD;
&#xD;
          -  Have any form of renal impairment&#xD;
&#xD;
          -  Have Cystic Fibrosis&#xD;
&#xD;
          -  Have Glucocorticoid-, Chemotherapeutic-, or any other Medication-induced form of&#xD;
             Diabetes&#xD;
&#xD;
          -  Be using any basal insulin other than Glargine insulin&#xD;
&#xD;
          -  Have cognitive impairment (&gt; 2 grades behind age-appropriate grade in school)&#xD;
&#xD;
          -  Be in Foster Care&#xD;
&#xD;
          -  Have any history of Division of Family and Children Services (DFCS) involvement&#xD;
&#xD;
          -  If female, be pregnant or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric I Felner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <results_first_submitted>September 2, 2021</results_first_submitted>
  <results_first_submitted_qc>September 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 30, 2021</results_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Eric Felner, MD, MSCR</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Glycemic variability</keyword>
  <keyword>Insulin</keyword>
  <keyword>Parental Stress</keyword>
  <keyword>Advanced carbohydrates counting</keyword>
  <keyword>Insulin for meals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT04157738/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fixed Group</title>
          <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
        </group>
        <group group_id="P2">
          <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
          <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Moved out of state</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not show up to the Follow-up appointment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fixed Group</title>
          <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
        </group>
        <group group_id="B2">
          <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
          <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="9" upper_limit="12.5"/>
                    <measurement group_id="B2" value="11" lower_limit="9" upper_limit="12"/>
                    <measurement group_id="B3" value="11" lower_limit="9" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Onset with Acidosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pubertal at onset</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of All Consented Participants</title>
        <description>The capacity for recruitment was assessed, including all subjects that signed the Informed Consent Form (ICF).</description>
        <time_frame>4 months post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
          <group group_id="O2">
            <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Consented Participants</title>
          <description>The capacity for recruitment was assessed, including all subjects that signed the Informed Consent Form (ICF).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Completed All Visits</title>
        <description>Number of participants that were able to complete all study visits, including the visits in-person at 1 month and 4 months post-randomization.</description>
        <time_frame>4 months post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
          <group group_id="O2">
            <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Completed All Visits</title>
          <description>Number of participants that were able to complete all study visits, including the visits in-person at 1 month and 4 months post-randomization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention</title>
        <description>Caregiver treatment adherence was assessed using a blood glucose log. Subjects and caregivers recorded blood glucose levels and the amount/type of insulin given. This data was used to calculate adherence as a percentage ranging from 0% (no adherence) to 100% (full adherence).</description>
        <time_frame>1 month post-intervention and 4 months post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
          <group group_id="O2">
            <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention</title>
          <description>Caregiver treatment adherence was assessed using a blood glucose log. Subjects and caregivers recorded blood glucose levels and the amount/type of insulin given. This data was used to calculate adherence as a percentage ranging from 0% (no adherence) to 100% (full adherence).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 4 times/day at 1-month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.0" upper_limit="16.1"/>
                    <measurement group_id="O2" value="10.2" lower_limit="2.4" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 4 times/day at 1-month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="83.9" upper_limit="100"/>
                    <measurement group_id="O2" value="89.8" lower_limit="78.6" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt; 4 times/day at 4-month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.0" upper_limit="12.6"/>
                    <measurement group_id="O2" value="16.1" lower_limit="2.0" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 4 times/day at 4-month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="87.4" upper_limit="100"/>
                    <measurement group_id="O2" value="83.9" lower_limit="61.8" upper_limit="98.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caregiver Anxiety</title>
        <description>Caregiver anxiety was measured with the &quot;parental stress scale&quot;. Caregivers completed the &quot;parental stress scale&quot; at initial enrollment and at each clinic follow up visit. The Parental Stress Scale includes 18 questions that are rated from 1 (strongly disagree) to 5 (strongly agree). Scoring ranges from 18 - 90. The higher the score, the higher the stress and anxiety level.</description>
        <time_frame>Baseline, 1 month post-intervention, 4 months post-intervention</time_frame>
        <population>Number of participants analyzed include subjects that had visits in-person at 1 month and 4 months post-randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Fixed Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
          <group group_id="O2">
            <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Anxiety</title>
          <description>Caregiver anxiety was measured with the &quot;parental stress scale&quot;. Caregivers completed the &quot;parental stress scale&quot; at initial enrollment and at each clinic follow up visit. The Parental Stress Scale includes 18 questions that are rated from 1 (strongly disagree) to 5 (strongly agree). Scoring ranges from 18 - 90. The higher the score, the higher the stress and anxiety level.</description>
          <population>Number of participants analyzed include subjects that had visits in-person at 1 month and 4 months post-randomization.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" lower_limit="24.3" upper_limit="34.0"/>
                    <measurement group_id="O2" value="30.2" lower_limit="25.3" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month post-intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" lower_limit="22.2" upper_limit="31.8"/>
                    <measurement group_id="O2" value="35.9" lower_limit="30.7" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 months post-intervention</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" lower_limit="22.7" upper_limit="32.6"/>
                    <measurement group_id="O2" value="34.4" lower_limit="29.3" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention</title>
        <description>The GV was calculated in all subjects using the average blood glucose levels collected from the daily blood glucose paper log. A subjective qualification system was used to label each subject's GV based on their blood glucose levels and an established glucose monitoring (GM) data system. Subjects are considered to have appropriate GV if their blood glucose levels are in the range of 80 mg/dL - 180 mg/dL. Percentage of participants within each specific average BG range is shown.</description>
        <time_frame>1 month post-intervention, 4 months post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fixed Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
          <group group_id="O2">
            <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
            <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention</title>
          <description>The GV was calculated in all subjects using the average blood glucose levels collected from the daily blood glucose paper log. A subjective qualification system was used to label each subject's GV based on their blood glucose levels and an established glucose monitoring (GM) data system. Subjects are considered to have appropriate GV if their blood glucose levels are in the range of 80 mg/dL - 180 mg/dL. Percentage of participants within each specific average BG range is shown.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BG &lt; 50 mg/dL at 1 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.0" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG 50-79 mg/dL at 1 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="4.7" upper_limit="14.7"/>
                    <measurement group_id="O2" value="8.3" lower_limit="5.2" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG 80-180 mg/dL at 1 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" lower_limit="48.9" upper_limit="70.0"/>
                    <measurement group_id="O2" value="63.2" lower_limit="54.0" upper_limit="74.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG 181-350 mg/dL at 1 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" lower_limit="13.3" upper_limit="37.7"/>
                    <measurement group_id="O2" value="26.8" lower_limit="17.1" upper_limit="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG &gt;350 mg/dL at 1 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.0" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG &lt; 50 mg/dL at 4 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG 50-79 mg/dL at 4 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="5.3" upper_limit="12.4"/>
                    <measurement group_id="O2" value="7.3" lower_limit="4.2" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG 80-180 mg/dL at 4 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" lower_limit="57.1" upper_limit="80.4"/>
                    <measurement group_id="O2" value="69.0" lower_limit="59.5" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG 181-350 mg/dL at 4 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" lower_limit="8.2" upper_limit="35.5"/>
                    <measurement group_id="O2" value="21.8" lower_limit="5.8" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG &gt;350 mg/dL at 4 month post-intervention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data collected during follow up (until 4 months post-intervention).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fixed Group</title>
          <description>Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
        </group>
        <group group_id="E2">
          <title>Insulin to Carbohydrate Ratio (ICR) Group</title>
          <description>Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen&#xD;
Rapid-Acting Insulin: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)&#xD;
Long acting insulin: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mentas Status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diabetic Keoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Felner</name_or_title>
      <organization>Emory University</organization>
      <phone>404-727-7651</phone>
      <email>efelner@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

